Coagulation factor (F) VIII is essential for hemostasis. After activation, it combines with activated FIX (FIXa) on anionic membranes to form the intrinsic tenase enzyme complex, responsible for activating FX in the rate-limiting step of sustained coagulation. Hemophilia A and hemophilia B are due to inherited deficiencies in the activity of FVIII and FIX, respectively. Treatment of hemophilia A over the last decade has benefited from improved understanding of FVIII biology, including its secretion pathway, its interaction with von Willebrand factor in circulation, the biochemical nature of its FIXa cofactor activity, the regulation of FVIIIa by inactivation pathways, and its surprising immunogenicity. This has facilitated biotechnology innovations with first-in-class examples of several new therapeutic modalities recently receiving regulatory approval for hemophilia A, including FVIII mimetic bispecific antibodies and recombinant adeno associated viral (rAAV) vector-based gene therapy. Biological insights into FVIII are also guiding the development and use of gain-of-function FVIII variants aimed at addressing limitations of first-generation rAAV vectors for hemophilia A. Several gain-of-function FVIII variants designed to have improved secretion are currently incorporated in second-generation rAAV vectors and have recently entered clinical trials. Continued mutually reinforcing advancements in the understanding of FVIII biology and treatments for hemophilia A will be necessary to achieve the ultimate goal of hemophilia therapy: normalizing hemostasis and optimizing well-being with minimal treatment burden for all patients worldwide. -
Skip Nav Destination
Review Article|
August 1, 2024
Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies
Benjamin J Samelson-Jones,
University of Pennsylvania
* Corresponding Author; email: samelsonjonesb@email.chop.edu
Search for other works by this author on:
Lindsey A. George,
Lindsey A. George
University of Pennyslvania School of Medicine, Philadelphia, Pennsylvania, United States
Search for other works by this author on:
Bhavya S Doshi
Bhavya S Doshi
University of Pennsylvania, United States
Search for other works by this author on:
Blood blood.2024023275.
Article history
Submitted:
May 7, 2024
Revision Received:
July 23, 2024
Accepted:
July 23, 2024
Citation
Benjamin J Samelson-Jones, Lindsey A. George, Bhavya S Doshi; Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies. Blood 2024; blood.2024023275. doi: https://doi.org/10.1182/blood.2023023275
Download citation file:
My Account
Sign InAdvertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal